Killed but metabolically active vaccines

Current Opinion in Biotechnology

Volumn 23, Issue 6, 2012, Pages 917-923

  Dubensky, Thomas W ^a   Skoble, Justin ^a   Lauer, Peter ^a   Brockstedt, Dirk G ^a  

^a Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20TH CENTURY; BROAD APPLICATION; FERRARI; IMMUNE RESPONSE; IMMUNE SYSTEMS; INFECTIOUS DISEASE; LIFE EXPECTANCIES; METABOLIC ACTIVITY; PROSTATE CANCERS; QUALITY OF LIFE; THERAPEUTIC VACCINES; VACCINE TECHNOLOGIES;

ANTIGENS; IMMUNOLOGY; VACCINES;

DISEASES;

BACILLUS VACCINE; BACTERIAL TOXIN; BACTERIAL VACCINE; BRUCELLA VACCINE; BURKHOLDERIA VACCINE; CANCER VACCINE; FRANCISELLA VACCINE; IMMUNOLOGICAL ADJUVANT; KILLED BUT METABOLICALLY ACTIVE VACCINE; MALARIA VACCINE; METHOXSALEN; PEPTIDE VACCINE; PLASMODIUM FALCIPARUM VACCINE; RECOMBINANT LISTERIA MONOCYTOGENES VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SALMONELLA TYPHIMURIUM VACCINE; SIPULEUCEL T; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN ANTIBODY REACTION; BIOTECHNOLOGY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLOSTRIDIUM DIFFICILE; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG POTENCY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; IONIZING RADIATION; IRRADIATION; LISTERIA MONOCYTOGENES; MELANOMA; NONHUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; QUALITY OF LIFE; REVIEW; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; VACCINE PRODUCTION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DNA REPAIR; FICUSIN; HUMANS; LEISHMANIA; LISTERIA MONOCYTOGENES; ULTRAVIOLET RAYS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 84869878539     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.04.005     Document Type: Review

References (35)

1. Brockstedt D.G., Bahjat K.S., Giedlin M.A., Liu W., Leong M., Luckett W., Gao Y., Schnupf P., Kapadia D., Castro G., et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005, 11:853-860.
2. Lai C., Cao H., Hearst J.E., Corash L., Luo H., Wang Y. Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. Anal Chem 2008, 80:8790-8798.
3. Irsch J., Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011, 38:19-31.
4. Sancar A., Sancar G.B. DNA repair enzymes. Annu Rev Biochem 1988, 29-67.
5. Skoble J., Beaber J.W., Gao Y., Lovchik J.A., Sower L.E., Liu W., Luckett W., Peterson J.W., Calendar R., Portnoy D.A., et al. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect Immun 2009, 77:1649-1663.
6. Lankowski A.J., Hohmann E.L. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. J Infect Dis 2007, 195:1203-1211.
7. Witte C.E., Archer K.A., Rae C.S., Sauer J.D., Woodward J.J., Portnoy D.A. Innate immune pathways triggered by Listeria monocytogenes and their role in the induction of cell-mediated immunity. Adv Immunol 2012, 113:135-156.
8. Le D.T., Brockstedt D.G., Nir-Paz R., Hampl J., Mathur S., Nemunaitis J., Sterman D.H., Hassan R., Lutz E., Moyer B., et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012, 18:858-868.
9. Le D, Dubensky TW, Brockstedt DG: Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol 2012, in press.
10. Lecuit M. Human listeriosis and animal models. Microbes Infect 2007.
11. Neuenhahn M., Kerksiek K.M., Nauerth M., Suhre M.H., Schiemann M., Gebhardt F.E., Stemberger C., Panthel K., Schroder S., Chakraborty T., et al. CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen. Immunity 2006, 25:619-630.
12. Schnupf P., Portnoy D.A. Listeriolysin O: a phagosome-specific lysin. Microbes Infect 2007.
13. Bahjat K.S., Liu W., Lemmens E.E., Schoenberger S.P., Portnoy D.A., Dubensky T.W., Brockstedt D.G. Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun 2006, 74:6387-6397.
14. Lauvau G., Vijh S., Kong P., Horng T., Kerksiek K., Serbina N., Tuma R.A., Pamer E.G. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 2001, 294:1735-1739.
15. Shetron-Rama L.M., Mueller K., Bravo J.M., Bouwer H.G., Way S.S., Freitag N.E. Isolation of Listeria monocytogenes mutants with high-level in vitro expression of host cytosol-induced gene products. Mol Microbiol 2003, 48:1537-1551.
16. Lauer P., Hanson B., Lemmens E.E., Liu W., Luckett W.S., Leong M.L., Allen H.E., Skoble J., Bahjat K.S., Freitag N.E., et al. Constitutive activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains. Infect Immun 2008, 76:3742-3753.
17. Greenberg R.N., Marbury T.C., Foglia G., Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012, 30:2245-2249.
18. Bruhn K.W., Birnbaum R., Haskell J., Vanchinathan V., Greger S., Narayan R., Chang P.L., Tran T.A., Hickerson S.M., Beverley S.M., et al. Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol 2012, 19:490-498.
19. Naegeli H., Sugasawa K. The xeroderma pigmentosum pathway: decision tree analysis of DNA quality. DNA Repair 2011, 10:673-683.
20. Passos-Silva D.G., Rajao M.A., Nascimento de Aguiar P.H., Vieira-da-Rocha J.P., Machado C.R., Furtado C. Overview of DNA repair in Trypanosoma cruzi, Trypanosoma brucei, and Leishmania major. J Nucleic Acids 2010, 2010:840768.
21. Lopez-Camarillo C., Lopez-Casamichana M., Weber C., Guillen N., Orozco E., Marchat L.A. DNA repair mechanisms in eukaryotes: special focus in Entamoeba histolytica and related protozoan parasites. Infect Genet Evol 2009, 9:1051-1056.
22. Datta S.K., Okamoto S., Hayashi T., Shin S.S., Mihajlov I., Fermin A., Guiney D.G., Fierer J., Raz E. Vaccination with irradiated listeria induces protective T cell immunity. Immunity 2006, 25:143-152.
23. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., Li T., Chakravarty S., Gunasekera A., Chattopadhyay R., Li M., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010, 6:97-106.
24. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., Gunasekera A., Chakravarty S., James E.R., Sedegah M., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 2011, 334:475-480.
25. Skoberne M., Yewdall A., Bahjat K.S., Godefroy E., Lauer P., Lemmens E., Liu W., Luckett W., Leong M., Dubensky T.W., et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest 2008.
26. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010, 363:411-422.
27. Di Lorenzo G., Buonerba C., Kantoff P.W. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011, 8:551-561.
28. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmuller B., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New Engl J Med 2011, 365:1863-1875.
29. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., Pathak M.A. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. New Engl J Med 1974, 291:1207-1211.
30. O'Riordan M., Yi C.H., Gonzales R., Lee K.D., Portnoy D.A. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A 2002, 99:13861-13866.
31. Woodward J.J., Iavarone A.T., Portnoy D.A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
32. Burdette D.L., Monroe K.M., Sotelo-Troha K., Iwig J.S., Eckert B., Hyodo M., Hayakawa Y., Vance R.E. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478:515-518.
33. Brockstedt D.G., Giedlin M.A., Leong M.L., Bahjat K.S., Gao Y., Luckett W., Liu W., Cook D.N., Portnoy D.A., Dubensky T.W. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004, 101:13832-13837.
34. Brockstedt D.G., Dubensky T.W. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 2008, 7:1069-1084.
35. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11:865-872.